Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q1 2021 · 10-Q
Revenue$2.42M$2.42M+2,058.6% vs Q1 2020 Net Income-$4.44M-$4.44MN/M vs Q1 2020 EPS Diluted-$0.19-$0.19N/M vs Q1 2020 Gross Profit$517,420+10,704.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flow-$3,620,039N/M Margins · derivedGross margin21.4%+17.1 pt vs Q1 2020
Operating margin-188.2%+1195.0 pt vs Q1 2020
Net margin-183.7%+2893.5 pt vs Q1 2020
ended Mar 31, 2021 · filed May 12, 2021 · 42 d after period end